MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
Clin Cancer Res
; 21(24): 5499-5510, 2015 Dec 15.
Article
in En
| MEDLINE
| ID: mdl-26272063
Full text:
1
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
/
Tumor Suppressor Protein p53
/
Protein Kinase Inhibitors
/
Mutation
/
Antineoplastic Agents
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2015
Type:
Article
Affiliation country:
Spain